Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism.
The effects of a beta 3-adrenoceptor agonist on insulin-induced changes in lipid metabolism were studied in obese male Zucker (fa/fa) rats during euglycaemic clamp. Rats were treated with BRL 35135 (R*, R*-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)-ethyl-amino]-propyl] phenoxyacetate hydrobromide) (0.5 mg/kg per day in drinking water) for three weeks before an euglycaemic hyperinsulinaemic clamp was performed. Insulin infusion lowered serum non-esterified fatty acids and plasma glycerol more efficiently in BRL 35135-treated than in control rats although plasma insulin remained significantly lower in the BRL 35135-treated than in the control rats during the clamp. In conclusion, chronic treatment with BRL 35135 potentiates the effect of insulin on lipid metabolism.
Virtanen
K A
KA
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland. kirsi.virtanen@utu.fi
Rouru
J
J
Hänninen
V
V
Savontaus
E
E
Rouvari
T
T
Teirmaa
T
T
Koulu
M
M
Huupponen
R
R
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D004357:Drug Synergism; D006946:Hyperinsulinism / Q000097:blood; D007328:Insulin / Q000494:pharmacology*; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008297:Male; D009765:Obesity / Q000378:metabolism; D010627:Phenethylamines / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker
D000318:Adrenergic beta-Agonists; D007328:Insulin; D008055:Lipids; D010627:Phenethylamines; C063157:BRL 35135